Hengrui Pharma(SH:600276) Mei Ri Jing Ji Xin Wen·2025-05-31 02:05Core Insights - On May 29, 2023, Heng Rui Medicine received approval for three innovative drugs, marking a significant achievement in the pharmaceutical industry [1][3] - The approval of these drugs reflects the increasing vibrancy of the innovative drug market in China, with a notable rise in capital market enthusiasm [2][5] Company Highlights - Heng Rui Medicine has now received approval for a total of 23 innovative drugs in China, with over 90 additional products in clinical development and approximately 400 clinical trials ongoing domestically and internationally [3] - The three newly approved drugs include: 1. Injection of Phosphororapitan Palonosetron (brand name: Ruitanning) for chemotherapy-induced nausea and vomiting 2. Self-developed HER2 ADC (antibody-drug conjugate) 3. Injection of Ruikang Trastuzumab (brand name: Aivida) for cervical cancer and non-small cell lung cancer [3] Industry Trends - The approval of 11 innovative drugs by the National Medical Products Administration (NMPA) on the same day has injected strong momentum into the pharmaceutical sector, with the Hang Seng Biotechnology Index showing a year-to-date increase of over 43% [5] - The upcoming 2025 American Society of Clinical Oncology (ASCO) annual meeting is expected to showcase a record number of presentations from Chinese experts, highlighting the growing international influence of Chinese innovative drug companies [6][7] - The market is witnessing a surge in innovative drug development, with many Chinese companies demonstrating strong potential for global expansion through licensing and other strategies [5][6]